Axiostat
Commercial- Indications
- Bleeding control, Vascular closure, Surgical hemostasis
Company intelligence / Profile preview
Axio Biosolutions has developed and commercialized a range of advanced wound care and hemostatic products. Their flagship product Axiostat—a chitosan-based hemostatic dressing—has received US FDA and CE approval for instant bleeding control. MaxioCel is another next-generation chitosan-based dressing for chronic wound management. The company’s products are used globally in trauma care (including military), surgery, emergency medicine, disaster relief, and chronic wound management[1][2].
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Axio Biosolutions.